After last release of safety data for M-M CYDY sai
Post# of 148170
Quote:
39% (11 SAEs in 28 Patients) in Placebo Arm as Compared to Only 14% (8 SAEs in 56 Patients) in Leronlimab Arm Reported Serious Adverse Events (SAEs), Which Were Unrelated to Leronlimab. The Efficacy Portion of the Trial Will Be Announced Along With a Full Report as Soon as Statistical Analyses Are Completed
Can somebody think why would CYDY call for a conference call and NOT announce the efficacy portion instead of rather wait until Statistical Analyses are completed & available ???
I can't and therefore think we will be given the results.